Goserelin Acetate

CHEMBL1200501 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1329.5 g/mol

LogP

—

Phase

4

The acetate salt form of goserelin, a gonadotropin-releasing hormone agonist delivered as a subcutaneous implant to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, and benign prostatic hyperplasia. After an initial flare in hormone levels, it produces sustained suppression beneficial in hormone-sensitive conditions. This is the commercially available formulation used in clinical practice.

Moleküler Ağırlık

1329,5000 g/mol

TPSA

533,00 Å²

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Non-Small Cell Lung Cancer Osteoporosis Schizophrenia Melanoma Lymphoma Hypertension Major Depressive Disorder Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O

InChI

InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1

Molecular Formula

C61H88N18O16

HBD / HBA

18 / 18

Döndürülebilir Bağlar

32

Ağır Atomlar

95

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The acetate salt form of goserelin, a gonadotropin-releasing hormone agonist delivered as a subcutaneous implant to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, and benign prostatic hyperplasia. After an initial flare in hormone levels, it produces sustained suppression beneficial in hormone-sensitive conditions. This is the commercially available formulation used in clinical practice.

Yes, Goserelin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200501. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16052011. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Goserelin Acetate PillFYI'da

Yapı

Hızlı Veriler

Formül: C61H88N18O16
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.